- Home
- ACAD
as 05-30-2025 4:00pm EST
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.5B | IPO Year: | 2004 |
| Target Price: | $27.08 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.40 - $25.23 | Next Earning Date: | 05-07-2025 |
| Revenue: | $996,283,000 | Revenue Growth: | 22.42% |
| Revenue Growth (this year): | 13.49% | Revenue Growth (next year): | 10.58% |
Stock Insider Trading Activity of ACADIA Pharmaceuticals Inc. (ACAD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | May 1 '25 | Sell | $14.60 | 1,327 | $19,374.20 | 23,526 | |
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Apr 5 '25 | Sell | $14.82 | 1,028 | $15,234.96 | 23,526 | |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | Apr 5 '25 | Sell | $14.82 | 2,708 | $40,132.56 | 59,456 | |
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Mar 24 '25 | Sell | $17.05 | 1,095 | $18,669.75 | 23,526 | |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | Mar 24 '25 | Sell | $17.05 | 3,171 | $54,065.55 | 59,456 | |
| GAROFALO ELIZABETH A. | ACAD | Director | Mar 5 '25 | Sell | $18.23 | 4,919 | $89,673.37 | 17,595 |
Latest ACADIA Pharmaceuticals Inc. News
ACAD Breaking Stock News: Dive into ACAD Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Business Wire
4 days ago
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
MT Newswires
10 days ago
Deutsche Bank Upgrades ACADIA Pharmaceuticals to Buy From Hold, Price Target is $20
Argus Research
11 days ago
ACAD: Raising target price to $23.00
Business Wire
11 days ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Insider Monkey
11 days ago
Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday
TipRanks
11 days ago
Biotech Alert: Searches spiking for these stocks today
Investor's Business Daily
12 days ago
ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93
Compare ACAD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACAD ACADIA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.